# US 2012/0253261 A1 · Systems and methods for optogenetic modulation of cells within a patient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253261 A1
- Document ID: US20120253261A1
- Status: Published application
- Kind: A1
- Application number: 13/074,808
- Filed: 2011-03-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Medtronic, Inc.
- Inventors: CHRISTOPHER POLETTO; JONATHON E. GIFTAKIS; WILLIAM F. KAEMMERER
- Web page: https://patentgrep.com/patent/US20120253261A1

## CPC

- A61N 5/0622: {Optical stimulation for exciting neural tissue}
- A61M 5/14276: {specially adapted for implantation}
- A61N 5/0601: {Apparatus for use inside the body}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61B 2017/00039: {Electric or electromagnetic phenomena other than conductivity, e.g. capacity, inductivity, Hall effect}
- A61N 2005/0612: {using probes penetrating tissue; interstitial probes}
- A61N 2005/063: {comprising light transmitting means, e.g. optical fibres}
- A61N 2005/0651: {Diodes}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Cells within a patient are optogenetically modulated to treat various neurological disorders. In one example, a method includes delivering a viral vector including a genetic agent encoding for one or more light-sensitive proteins to a delivery site within a patient. The viral vector includes retrograde and/or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of sites proximal and remote to the delivery site. A bioelectrical signal(s) related to a neurological condition of the patient is sensed, e.g. using an implanted electrode. Optical stimulation is delivered to cells transduced with the genetic agent by the viral vector to treat the neurological condition of the patient.

## Claims

### Claim 1

A method comprising:
delivering a viral vector comprising a genetic agent encoding for one or more light-sensitive proteins to a delivery site within a patient, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of sites proximal and remote to the delivery site;
sensing a bioelectrical signal related to a neurological condition of the patient; and
delivering optical stimulation to one or more cells transduced with the genetic agent by the viral vector based on the sensed bioelectrical signal.

### Claim 2 (depends on 1)

The method of claim 1, wherein delivering the viral vector comprises at least one of delivering the viral vector to the delivery site intravenously or delivering the viral vector to the delivery site intracranially.

### Claim 3 (depends on 1)

The method of claim 1, wherein the viral vector comprises at least one of adeno-associated virus (AAV), herpes simplex virus (HSV), or lentivirus.

### Claim 4 (depends on 1)

The method of claim 1, wherein the viral vector comprises at least one of a single-stranded nucleic acid or a self-complementary nucleic acid viral vector.

### Claim 5 (depends on 1)

The method of claim 1, wherein the viral vector comprises at least one of AAV serotype 9 or AAV serotype 2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more light-sensitive proteins comprise at least one of Channelrhodopsin-2 (ChR2), halorhodopsin (NpHR), archaerhodopsin-3 from Halorubrum sodomense (Arch), archaerhodopsin from Halorubrum strain TP009 (ArchT), or a blue-green light-drivable proton pump from the fungus Leptosphaeria maculans (Mac).

### Claim 7 (depends on 1)

The method of claim 1, wherein the bioelectrical signal comprises at least one of a local field potential (LFP) of tissue of the patient, a signal associated with an electrocorticography (ECoG) of the brain of the patient, or a signal associated with an electroencephalography (EEG) of the brain of the patient.

### Claim 8 (depends on 1)

The method of claim 1, wherein delivering the viral vector comprises delivering the viral vector to a delivery site within the brain of the patient.

### Claim 9 (depends on 8)

The method of claim 8, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of ipsilateral and contralateral sites within the brain of the patient.

### Claim 10 (depends on 1)

The method of claim 1, wherein delivering the viral vector comprises delivering the viral vector to the hippocampus within a first hemisphere of the brain of the patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells in the hippocampus in the first hemisphere of the brain of the patient and into cells in a plurality of ipsilateral and contralateral sites within the brain of the patient.

### Claim 12 (depends on 11)

The method of claim 11, wherein the plurality of ipsilateral and contralateral sites within the brain of the patient comprises at least one of the hippocampus in a second hemisphere of the brain of the patient or the cerebral cortex of the brain of the patient.

### Claim 13 (depends on 1)

The method of claim 1, wherein delivering optical stimulation comprises delivering light to one or more of the cells transduced with the genetic agent by the viral vector, wherein the light is configured to activate at least one of the plurality of light-sensitive proteins in the one or more of the cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering at least one of a visible light comprising a wavelength in a range between from 380 nm to about 750 nm, an infrared light comprising a wavelength in a range between from 700 nm to about 300 μm, or an ultraviolet light comprising a wavelength from about 10 nm to about 400 nm.

### Claim 15 (depends on 13)

The method of claim 13, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength in a range from about 420 nm to about 500 nm.

### Claim 16 (depends on 15)

The method of claim 15, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength in a range from about 450 nm to about 495 nm.

### Claim 17 (depends on 16)

The method of claim 16, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength equal to about 470 nm.

### Claim 18 (depends on 13)

The method of claim 13, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength in a range from about 495 nm to about 570 nm.

### Claim 19 (depends on 18)

The method of claim 18, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength in a range from about 510 nm to about 550 nm.

### Claim 20 (depends on 19)

The method of claim 19, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength equal to about 535 nm.

### Claim 21 (depends on 13)

The method of claim 13, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength in a range from about 550 nm to about 610 nm.

### Claim 22 (depends on 21)

The method of claim 21, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength in a range from about 570 nm to about 590 nm.

### Claim 23 (depends on 22)

The method of claim 22, wherein delivering the light to the one or more of the cells transduced with the genetic agent by the viral vector comprises delivering a light comprising a wavelength equal to about 580 nm.

### Claim 24 (depends on 1)

The method of claim 1, wherein delivering optical stimulation comprises delivering a first light comprising a first wavelength to one or more of the cells transduced with the genetic agent by the viral vector and delivering a second light comprising a second wavelength to one or more of the cells transduced with the genetic agent by the viral vector.

### Claim 25 (depends on 24)

The method of claim 24, wherein the first wavelength is different than the second wavelength.

### Claim 26 (depends on 24)

The method of claim 24, wherein the first light is configured to activate at least one of the plurality of light-sensitive proteins in the one or more of the cells and the second light is configured to activate at least one other of the plurality of light-sensitive proteins in the one or more of the cells.

### Claim 27

A medical system comprising:
a biological vector delivery device configured to deliver a viral vector comprising a genetic agent encoding for one or more light-sensitive proteins to a delivery site within a patient, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of sites proximal and remote to the delivery site;
a sensor configured to sense a bioelectrical signal related to a neurological condition of the patient; and
an optical stimulator configured to deliver light to one or more of the cells transduced with the genetic agent by the viral vector based on the bioelectrical signal sensed by the sensor.

### Claim 28 (depends on 27)

The system of claim 27, wherein the optical stimulator comprises:
at least one light source configured to generate light; and
at least one optical fiber connected to the light source and configured to deliver the light generated by the light source to the one or more of the cells transduced with the genetic agent by the viral vector; and
a processor configured to control the light source to generate light configured to activate at least one of the plurality of light-sensitive proteins in the one or more of the cells transduced with the genetic agent by the viral vector.

### Claim 29 (depends on 28)

The system of claim 28, further comprising a plurality of optrodes connected to the at least one optical fiber and configured to deliver the at least one light generated by the light source to cells in one or more locations corresponding to the respective locations of the optrodes.

### Claim 30 (depends on 29)

The system of claim 29, wherein the at least one optical fiber comprises a plurality of optical fibers connected to the plurality of optrodes such that each of the optrodes is configured to deliver the at least one light generated by the light source to one or more of the cells transduced with the genetic agent by the viral vector.

### Claim 31 (depends on 29)

The system of claim 29, wherein the at least one optical fiber comprises a plurality of optical fibers connected to the plurality of optrodes such that each of a plurality of groups of the plurality of optrodes is configured to deliver the at least one light generated by the light source to one or more of the cells transduced with the genetic agent by the viral vector.

### Claim 32 (depends on 27)

The system of claim 27, wherein the biological vector delivery device is configured to deliver the viral vector to at least one of delivering the viral vector to the delivery site intravenously or delivering the viral vector to the delivery site intracranially.

### Claim 33 (depends on 27)

The system of claim 27, wherein the biological vector delivery device comprises a catheter configured to inject the viral vector into the brain of the patient intracranially.

### Claim 34 (depends on 27)

The system of claim 27, wherein the viral vector comprises at least one of adeno-associated virus (AAV), herpes simplex virus (HSV), or lentivirus.

### Claim 35 (depends on 27)

The system of claim 27, wherein the viral vector comprises at least one of a single-stranded nucleic acid or a self-complementary nucleic acid viral vector.

### Claim 36 (depends on 27)

The system of claim 27, wherein the viral vector comprises at least one of AAV serotype 9 or AAV serotype 2.

### Claim 37 (depends on 27)

The system of claim 27, wherein the one or more light-sensitive proteins comprise at least one of Channelrhodopsin-2 (ChR2), halorhodopsin (NpHR), archaerhodopsin-3 from Halorubrum sodomense (Arch), archaerhodopsin from Halorubrum strain TP009 (ArchT), or a blue-green light-drivable proton pump from the fungus Leptosphaeria maculans (Mac).

### Claim 38 (depends on 27)

The system of claim 27, wherein the sensor comprises an electrode configured to sense at least one of a local field potential (LFP) of tissue of the patient, a signal associated with an electrocorticography (ECoG) of the brain of the patient, or a signal associated with an electroencephalography (EEG) of the brain of the patient.

### Claim 39 (depends on 27)

The system of claim 27, wherein the biological vector delivery device is configured to deliver the viral vector to a delivery site within the brain of the patient.

### Claim 40 (depends on 39)

The system of claim 39, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of ipsilateral and contralateral sites within the brain of the patient.

### Claim 41 (depends on 27)

The system of claim 27, wherein the biological vector delivery device is configured to deliver the viral vector to the hippocampus within a first hemisphere of the brain of the patient.

### Claim 42 (depends on 41)

The system of claim 41, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells in the hippocampus in the first hemisphere of the brain of the patient and into cells in a plurality of ipsilateral and contralateral sites within the brain of the patient.

### Claim 43 (depends on 42)

The system of claim 42, wherein the plurality of ipsilateral and contralateral sites within the brain of the patient comprises at least one of the hippocampus in a second hemisphere of the brain of the patient or the cerebral cortex of the brain of the patient.

### Claim 44

A system comprising:
means for delivering a viral vector comprising a genetic agent encoding for one or more light-sensitive proteins to a delivery site within a patient, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of sites proximal and remote to the delivery site;
means for sensing a bioelectrical signal related to a neurological condition of the patient; and
means for delivering optical stimulation to one or more cells transduced with the genetic agent by the viral vector based on the bioelectrical signal.

### Claim 45

A method comprising:
delivering a viral vector comprising a genetic agent encoding for one or more light-sensitive proteins to a delivery site in the hippo campus within a first hemisphere of the brain of a patient, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of sites proximal and remote to the delivery site;
sensing a bioelectrical signal related to epilepsy; and
delivering optical stimulation to one or more cells transduced with the genetic agent in the cerebral cortex of the brain of the patient based on the sensed bioelectrical signal.

### Claim 46

A medical system comprising:
a biological vector delivery device configured to deliver a viral vector comprising a genetic agent encoding for one or more light-sensitive proteins to a delivery site in the hippocampus within a first hemisphere of the brain of a patient, wherein the viral vector comprises at least one of retrograde or anterograde transport properties such that the viral vector is configured to transduce the genetic agent into cells at the delivery site and into cells in a plurality of sites proximal and remote to the delivery site;
a sensor configured to sense a bioelectrical signal related to epilepsy; and
an optical stimulator configured to deliver light to one or more of the cells transduced with the genetic agent in the cerebral cortex of the brain of the patient based on the bioelectrical signal sensed by the sensor.
